(Q85948911)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

chronic lymphocytic leukemia

22 February 2020

main subject

1 reference

Claire E Dearden

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sue Richards

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Monica Else

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Daniel Catovsky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter Hillmen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

14 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

2452-2460

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25776

7 January 2021

Identifiers

DOI

10.1002/CNCR.25776

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24048793%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference